|
|
| Line 1: |
Line 1: |
| [[Image:2hwp.jpg|left|200px]] | | {{Seed}} |
| | [[Image:2hwp.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_2hwp| PDB=2hwp | SCENE= }} | | {{STRUCTURE_2hwp| PDB=2hwp | SCENE= }} |
|
| |
|
| '''Crystal structure of Src kinase domain in complex with covalent inhibitor PD168393'''
| | ===Crystal structure of Src kinase domain in complex with covalent inhibitor PD168393=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-molecule inhibitors. We report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue. Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src). To accommodate the new covalent bond, the quinazoline core adopts positions that are different from those seen in kinase structures with reversible quinazoline inhibitors. Based on these structures, we developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe to report the fraction of kinase necessary for cellular signaling, and we used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.
| | The line below this paragraph, {{ABSTRACT_PUBMED_17334377}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 17334377 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_17334377}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| Line 30: |
Line 34: |
| [[Category: Modification]] | | [[Category: Modification]] |
| [[Category: Quinazoline]] | | [[Category: Quinazoline]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 06:48:24 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 08:01:41 2008'' |
